BioSpace News Archive

Mindset Pharma Inc. today announced data from preclinical studies comparing its novel prodrug of psilocin, MSP-1014.

Organon today announced the availability and distribution of Ontruzant ® , a biosimilar of Herceptin ® , providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).

Aerovate Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2022, and recent business highlights.

SELLAS Life Sciences Group, Inc. today announced important updates relating to its ongoing Phase 3 open-label registrational clinical trial (the REGAL study) for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients who have achieved complete remission following second-line salvage therapy (CR2 patients).

EVERSANA ®, a pioneer of next-generation commercial services to the global life sciences industry, today named Sy Pretorius as the company’s new Chief Operating Officer and President, Outsourced Solutions.

Revolo Biotherapeutics announced that it will be participating in the TIDES Europe 2022 Conference on Oligonucleotide & Peptide Therapeutics, being held virtually and in-person in Vienna, Austria, from November 16-18.

MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41st Annual National Society of Genetic Counselors meeting, Nov. 16-19 in Nashville, Tenn.

Cocrystal Pharma, Inc. reports financial results for the three and nine months ended September 30, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2022 and provided an update on the company’s business and clinical development progress.